Karuna Therapeutics — Technical Presentation (November 2019)
19 slides from Karuna Therapeutics's technical presentation, Nov 18, 2019
Slide 1: Topline Data from Phase 2 Trial of KarXT in Acute Psychosis in Schizophrenia
Developing novel therapies to dramatically improve the lives of people with psychiatric and neurological disorders Topline Data from Phase 2 Trial of KarXT in Acute Psychosis in Patients with Schizophrenia Exhibit 99.2
Slide 2: Legal Disclaimer
Legal Disclaimer OVERVIEW These slides and the accompanying oral presentation contain forward-looking statements and information. You should not place undue reliance on forward-looking statements, as these statements are based upon our current expectations, forecasts, and assumptions and are subject
Slide 3: Agenda
IntroductionTroy Ignelzi / Chief Financial Officer Summary of Phase 2 ResultsSteve Paul, M.D. / Chairman, CEO and President Phase 2 Results AnalysisStephen Brannan, M.D. / Chief Medical Officer KarXT Development PlanAndrew Miller, Ph.D. / Founder & Chief Operating Officer Summary RemarksSteve Paul,
Slide 4: KarXT Phase 2 Trial Results in Acute Psychosis in Patients with Schizophrenia
KarXT Phase 2 Trial Results in Acute Psychosis in Patients with Schizophrenia
Slide 5: Schizophrenia: The "cancer of psychiatry"
Chronic, disabling disorder typically diagnosed in late teenage years or early adulthood Characterized by recurring episodes of psychosis requiring long-term treatment with antipsychotic drugs in most patients Affects over 21 million people worldwide 2.7 million Americans (0.5% - 1.0% of U.S. popula
Slide 6: Summary of Topline Results
Summary of Topline Phase 2 Results Summary of Phase 2 Results KarXT is a novel mechanism of action therapeutic targeting central nervous system (CNS) indications representing large and underserved patient populations characterized by psychosis and cognitive impairment Met the primary endpoint with a
Slide 7: KarXT Phase 2 Trial Results Analysis
KarXT Phase 2 Trial Results Analysis
Slide 8: Phase 2 Trial Design Overview
Phase 2 Trial Design Overview Same fundamental trial design and primary endpoint used in pivotal studies to support registration of other antipsychotic drugs Randomized, double-blind, placebo-controlled, five week, inpatient trial Enrolled 182 schizophrenia patients with acute psychosis (N=90 on Kar
Slide 9: Demographics and Baseline Characteristics
Demographics and Baseline Characteristics Phase 2 Results Analysis Placebo KarXT Mean age (years) 41.8 43.7 Sex, male (%) 74 81 Race (%white / %non-white) 20/80 23/77 Baseline PANSS 96.6 97.3 Baseline PANSS-positive 26.3 26.3 Baseline PANSS-negative 22.9 22.5 mITT population No significant differenc
Slide 10: Primary Endpoint: PANSS Total Score at Week 5
Baseline Week 2 Week 4 Week 5 *** *** *** Clinically meaningful and statistically significant improvement in total PANSS vs placebo 11.6 point improvement at week 5 with p<0.0001 (-17.4 KarXT vs. -5.9 placebo) Statistical separation at every assessed time point Primary Endpoint: PANSS Total Score at
Slide 11: Secondary Endpoint: PANSS-Positive Subscore
Clinically meaningful and statistically significant improvement in total PANSS-positive vs placebo 3.2 point improvement at week 5 with p<0.0001 (-5.6 KarXT vs. -2.4 placebo) Statistical separation at every assessed time point Secondary Endpoint: PANSS-Positive Subscore Phase 2 Results Analysis Base
Slide 12: Secondary Endpoint: PANSS-Negative Subscore
Clinically meaningful and statistically significant improvement in PANSS-negative vs placebo 2.3 point improvement at week 5 with p<0.001 (-3.2 KarXT vs. -0.9 placebo) Statistical separation at every assessed time point Secondary Endpoint: PANSS-Negative Subscore Phase 2 Results Analysis Baseline We
Slide 13: KarXT was well tolerated
KarXT was well tolerated Overall discontinuation rate on KarXT (20%) similar to placebo (21%) The number of discontinuations due to treatment emergent adverse events was equal in the KarXT and placebo arms (N=2 in each group) Dose escalation rate on KarXT was high and similar to placebo 91% of KarXT
Slide 14: KarXT Development Plan
Development Plan KarXT | | n | WY) by ZH
Slide 15: Development of KarXT
Achieved the initial goals of KarXT development: Improve tolerability of xanomeline Maintain and confirm previous therapeutic benefits of xanomeline Three double-blind, placebo-controlled studies supporting therapeutic benefit of xanomeline/KarXT KarXT Phase 2 study in patients with schizophrenia Sm
Slide 16: KarXT Development Moving Forward
Complete final analysis of all data and endpoints to further inform path forward Plan an end of Phase 2 meeting with FDA to discuss data and development path including Phase 3 trial design Meeting anticipated in Q2 2020 Pending FDA meeting, we anticipate advancing to Phase 3 using a similar trial de
Slide 17: Karuna's portfolio of muscarinic receptor-targeted programs
Karuna’s portfolio of muscarinic receptor-targeted programs THE KarXT Development Plan Indication Discovery/ Preclinical Phase 1 Phase 2 Phase 3 Upcoming Milestone Schizophrenia Psychosis Schizophrenia Cognitive Symptoms Schizophrenia Negative Symptoms Alzheimer’s Disease Psychosis Pain Muscarinic T
Slide 18: Summary Comments
Summary Comments
Slide 19: Developing novel therapies to dramatically improve the lives of people with psychiatric and neurological
Developing novel therapies to dramatically improve the lives of people with psychiatric and neurological disorders
Karuna Therapeutics — Technical Presentation (November 2019) on 6ix